The IPO, to raise Rs 1,741 crore, received bids for 1,20,33,096 shares against the total issue size of 1,59,48,750 shares, data available with the NSE showed.
The portion set aside for qualified institutional buyers (QIBs) was subscribed 82 per cent, non institutional investors 3 per cent and retail investors 1.68 times.
Eris Lifesciences last week mopped up Rs 779 crore from 21 anchor investors.
The price band for the share sale has been fixed at Rs 600-603.
The offer, which closes tomorrow, comprises sale of 2.89 crore shares.
Eris Lifesciences is into manufacturing of branded pharmaceutical products in select therapeutic areas.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
